Abstract
Efficacy and safety are the two key elements in the drug discovery and development processes. The primary goal for pharmaceutical research companies is to identify and manufacture therapeutic agents that are safe and efficacious for patients. In principle, benefits versus risks have to be considered for target patient populations. The risks are relatively high in life threatening diseases, e.g. cancer, compared to general areas, e.g. inflammation. Pharmacology, medicinal chemistry, pharmaceutical sciences, safety assessment, drug metabolism and pharmacokinetics (DMPK), clinical research, etc. are the essential multidisciplinary R&D functions assembled within the pharmaceutical R&D engine to accomplish the aforementioned mission. Pharmacokinetics (PK) is generally viewed as the universal biomarker which reflects the processes of how a drug molecule is absorbed (e.g. ka), distributed (e.g. Vd) in the body, and cleared from the body through metabolism and excretion. The area under the drug plasma concentration versus time curve (AUC) provides an indirect assessment of the exposure level and duration of action of the therapeutic agent at the site of action (e.g. synovial fluid, tumor, brain). An ideal drug candidate should possess a plasma drug level which is above the therapeutic concentration (i.e. efficacious) and below the toxic concentration (i.e. safe). In general, the therapeutic index is calculated by dividing the plasma exposure at the NO (toxic) Effect Level (NOEL), or NO Adverse Effect Level (NOAEL), by the minimum plasma concentration required for efficacy (e.g. EC50) and the safety margin is calculated by dividing NOEL (or NOAEL) plasma concentration by the maximum plasma drug concentration (Cmax) achieved at an efficacious dose.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Balani SK, Zhu T, Yang TJ, Liu Z, He B, and Lee FW. Effective Dosing Regimen of 1-Aminobenzotriazole for Inhibition of Antipyrine Clearance in Rats, Dogs and Monkeys. Drug Metab Dispos 2002; 30:1059–1062.
Balani S, Li P, Nguyen J, Cardoza K, Zeng H, Mu DX, Wu JT, Gan LS, Lee FW. Effective Dosing Regimen of 1-aminobenzotriazole for Inhibition of Antipyrine Clearance in Guinea Pigs and Mice using Serial Sampling. Drug Metab Dispos 2004; 32, 1092–1095.
Constan AA, Sprankle CS, Peters JM, Kedderis GL, Everitt JI, Gonzalez FL, and Butterworth BE. Metabolism of Chloroform by CYP 2E1 is Required for Induction of Toxicity in the Liver, Kidney and Nose of Male Mice. Toxicol Appl Pharmacol 1999; 160:120–126.
Huijzer JC, Adams JD, Jaw JY, and Yost GS. Inhibition of 3-Methylindole Bioactivation by Cytochrome P450 Suicide Substrate 1-Aminobenzotriazole and ·-Methylbenzylamino-benzotriazole. Drug Metab Dispos 1 1989; 17:37–42.
Johnston MM, Rosenberg M, Dorsey TE, Doyle RF. Automated Analysis of Chlorthalidone Based on the Inhibition of Carbonic Anhydrase. Methodological Surveys 1981; 10:253–8.
Li P, Labutti J, Lu C, Daniels JS, Nagaraja N, Huang R, Gallegos R, Uttamsingh V, Balani SK, Lee FW, Miwa G, and Gan LS. N-Acetylation of a Primary Alkylamine as a Major Metabolic Clearance Route in Rats. Drug Metabolism Rev 2004; 36(S1):327.
Lettieri JT, Portelli ST. Effects of Competitive Red Blood Cells Binding and Reduced Hematocrit on the Blood and Plasma Levels of [14C]Indapamide in the Rat. Journal of Pharmacology and Experimental Therapeutics 1983; 224:269–72.
Lohmann C, Huwel S, Galla HJ. Predicting Blood-Brain Barrier Permeability of Drugs: Evaluation of Different In Vitro Assays. Journal of Drug Targeting 2002; 10:263–276.
Lombardo F, Obach RS, Shalaeva MY, Gao F. Prediction of Human Volume of Distribution Values for Neutral and Basic Drugs. 2. Extended Data Set and Leave-Class-Out Statistics. Journal of Medicinal Chemistry 2004; 47:1242–1250.
Lombardo F, Obach RS, Shalaeva MY, Gao F. Prediction of Volume of Distribution Values in Humans for Neutral and Basic Drugs Using Physicochemical Measurements and Plasma Protein Binding Data. Journal of Medicinal Chemistry 2002; 45:2867–2876.
Lu C, Li P, Gallegos R, Xia C, Uttamsingh V, Miwa G, and Gan LS. Comparison of Intrinsic Clearance in Liver Microsomes, S9, and Hepatocytes from Rats and Humans. Drug Metabolism Rev 2004; 36(S1), 429.
Marsilje TH, Roses JB, Calderwood EF, Stroud SG, Forsyth NE, Blackburn C, Yowe DL, Miao W, Drabic SV, Bohane MD, Daniels JS, Li P, Wu L, Patane MA, Claiborne CF. Synthesis and Biological Evaluation of Imidazole-based Small Molecule Antagonists of the Melanocortin 4 Receptor (MC4-R). Bioorganic & Medicinal Chemistry Letters 2004; 14:3721–3725.
Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. Journal of Pharmaceutical Sciences 2002; 91:129–156.
Sharer JE, and Wrighton SA, “Identification of the Human Hepatic Cytochromes P450 Involved in the In Vitro Oxidation of Antipyrine”, Dug Metab Dispos 1996; 24:487–494.
Sharer JE, and Wrighton SA, “Identification of the Human Hepatic Cytochromes P450 Involved in the In Vitro Oxidation of Antipyrine”, Dug Metab Dispos 1996; 24:487–494.
Vos TJ, Caracoti A, Che JL, Dai M, Farrer CA, Forsyth NE, Drabic SV, Horlick RA, Lamppu D, Yowe DL, Balani S, Li P, Zeng H, Joseph IBJK, Rodriguez LE, Maguire MP, Patane MA, Claiborne CF. Identification of 2-2-[2-(5-Bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl-4,5-dihydro-1H-imidazole (ML00253764), a Small Molecule Melanocortin 4 Receptor Antagonist that Effectively Reduces Tumor-Induced Weight Loss in a Mouse Model. Journal of Medicinal Chemistry 2004; 47:1602–1604.
Wong BK, Bruhin PJ, Lin JH. Dos-dependent Pharmacokinetics of L-693,612, a Carbonic Anhydrase Inhibitor, Following Oral Administration n Rats. Pharmaceutical Research 1994; 11:438–441.
Yin W, Li P, Gan LS, Lodenquai P, Wu JT, Cardoza K, Yang H, Lee FW and Miwa G. Pharmacokinetics and Brian Uptake of Substituted 1,2-Diaryl-Ethane Melanocortin 4 (MC4) Receptor Antagonists in Rats. Drug Metabolism Rev 2004; 36(S1): 167.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Gan, LS. et al. (2006). Case History — Use of ADME Studies for Optimization of Drug Candidates. In: Borchardt, R.T., Kerns, E.H., Hageman, M.J., Thakker, D.R., Stevens, J.L. (eds) Optimizing the “Drug-Like” Properties of Leads in Drug Discovery. Biotechnology: Pharmaceutical Aspects, vol IV. Springer, New York, NY. https://doi.org/10.1007/978-0-387-44961-6_4
Download citation
DOI: https://doi.org/10.1007/978-0-387-44961-6_4
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-34056-2
Online ISBN: 978-0-387-44961-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
